Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AKST4290 + Aflibercept in Newly Diagnosed Wet AMD
NCT04331730Phase 2Completed
- Sponsor
- Alkahest, Inc.
- Start
- Jan 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of BI 144807 in neovascular age-related macular degeneration (NVAMD), sponsored by Alkahest, Inc.. Started Jan 2020; status: completed.
02
Drugs
BI 144807
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04331730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04331730.